New EMA powers have come into force
The European Medicine Agency’s new role in European crisis preparedness was tested during the Covid-19 pandemic, and has now been made permanent.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
On March 1, EU Regulation to extend the European Medicines Agency’s (EMA) mandate came into effect, meaning that the agency’s more improvised role during the Covid-19 pandemic has now been set in stone.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA gains more power to monitor medicines
For subscribers
HERA launches first work plan with millions in R&D financing
For subscribers
New EU portal for clinical trials launches on Monday
For subscribers
